RAPT Therapeutics (RAPT) Stock Forecast, Price & News

RAPT Therapeutics (NASDAQ:RAPT) Frequently Asked Questions

Is RAPT Therapeutics a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RAPT Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RAPT Therapeutics stock.
View analyst ratings for RAPT Therapeutics or view top-rated stocks.

When is RAPT Therapeutics' next earnings date?

RAPT Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for RAPT Therapeutics.

How were RAPT Therapeutics' earnings last quarter?

RAPT Therapeutics, Inc. (NASDAQ:RAPT) posted its quarterly earnings results on Wednesday, May, 11th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by $0.01. RAPT Therapeutics had a negative trailing twelve-month return on equity of 37.82% and a negative net margin of 2,263.55%.
View RAPT Therapeutics' earnings history.

What price target have analysts set for RAPT?

7 brokers have issued 1-year target prices for RAPT Therapeutics' shares. Their forecasts range from $30.00 to $72.00. On average, they expect RAPT Therapeutics' share price to reach $54.43 in the next year. This suggests a possible upside of 312.7% from the stock's current price.
View analysts' price targets for RAPT Therapeutics or view top-rated stocks among Wall Street analysts.

Who are RAPT Therapeutics' key executives?

RAPT Therapeutics' management team includes the following people:

• Dr. Brian Russell Wong M.D., Ph.D., CEO, Pres & Director (Age 50, Pay $783k)
• Mr. Rodney K. B. Young, CFO, Principal Accounting Officer & Sec. (Age 59, Pay $561.91k)
• Dr. William Ho, Chief Medical Officer (Age 56, Pay $564.44k) (LinkedIn Profile)
• Steve Young Ph.D., VP of Technology
• Dr. Dirk G. Brockstedt Ph.D., Chief Scientific Officer (Age 53) (LinkedIn Profile)
• Dr. Paul Kassner, Sr. VP of Quantitative & Computational Biology (Age 55)
• Dr. David Wustrow, Sr. VP of Drug Discovery & Preclinical Devel. (Age 63)

What is Brian Wong's approval rating as RAPT Therapeutics' CEO?

8 employees have rated RAPT Therapeutics CEO Brian Wong on Glassdoor.com. Brian Wong has an approval rating of 100% among RAPT Therapeutics' employees. This puts Brian Wong in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of RAPT Therapeutics' key competitors?

Some companies that are related to RAPT Therapeutics include Xenon Pharmaceuticals (XENE), Travere Therapeutics (TVTX), Supernus Pharmaceuticals (SUPN), Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO), Xencor (XNCR), Arcus Biosciences (RCUS), Dynavax Technologies (DVAX), BELLUS Health (BLUSF), Sierra Oncology (SRRA), 23andMe (ME), IVERIC bio (ISEE), Prothena (PRTA), Axsome Therapeutics (AXSM) and Prometheus Biosciences (RXDX).
View all of RAPT's competitors.

What other stocks do shareholders of RAPT Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RAPT Therapeutics investors own include NVIDIA (NVDA), Boeing (BA), Slack Technologies (WORK), Overstock.com (OSTK), Salesforce (CRM), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Livongo Health (LVGO), Mastercard (MA) and QUALCOMM (QCOM).

When did RAPT Therapeutics IPO?

(RAPT) raised $39 million in an initial public offering (IPO) on Thursday, October 31st 2019. The company issued 3,000,000 shares at a price of $12.00-$14.00 per share. BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank served as the underwriters for the IPO.

What is RAPT Therapeutics' stock symbol?

RAPT Therapeutics trades on the NASDAQ under the ticker symbol "RAPT."

Who are RAPT Therapeutics' major shareholders?

RAPT Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include State Street Corp (4.56%), Vanguard Group Inc. (4.14%), Woodline Partners LP (1.21%), Wellington Management Group LLP (1.02%), Dimensional Fund Advisors LP (0.96%) and Ghost Tree Capital LLC (0.85%). Company insiders that own RAPT Therapeutics stock include Brian Russell Wong, Dirk G Brockstedt, Dirk G Brockstedt, Gino Dellomo, Group Ii Lp Column, Karen C Lam, Michael F Giordano, Peter Svennilson, Phuong Y Phillips, Rodney Kb Young, Wendye Robbins and William Ho.
View institutional ownership trends for RAPT Therapeutics.

Which major investors are selling RAPT Therapeutics stock?

RAPT stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Ghost Tree Capital LLC, Citigroup Inc., UBS Group AG, Ensign Peak Advisors Inc, J. Goldman & Co LP, TD Asset Management Inc., and Metropolitan Life Insurance Co NY. Company insiders that have sold RAPT Therapeutics company stock in the last year include Dirk G Brockstedt, Gino Dellomo, Group Ii Lp Column, Phuong Y Phillips, and William Ho.
View insider buying and selling activity for RAPT Therapeutics or view top insider-selling stocks.

Which major investors are buying RAPT Therapeutics stock?

RAPT stock was acquired by a variety of institutional investors in the last quarter, including Woodline Partners LP, Candriam Luxembourg S.C.A., State Street Corp, Dimensional Fund Advisors LP, The Manufacturers Life Insurance Company , Renaissance Technologies LLC, Vanguard Group Inc., and Walleye Capital LLC. Company insiders that have bought RAPT Therapeutics stock in the last two years include Brian Russell Wong, Group Ii Lp Column, Rodney Kb Young, and Wendye Robbins.
View insider buying and selling activity for RAPT Therapeutics or or view top insider-buying stocks.

How do I buy shares of RAPT Therapeutics?

Shares of RAPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RAPT Therapeutics' stock price today?

One share of RAPT stock can currently be purchased for approximately $13.19.

How much money does RAPT Therapeutics make?

RAPT Therapeutics has a market capitalization of $390.95 million and generates $3.81 million in revenue each year. The company earns $-69.20 million in net income (profit) each year or ($2.56) on an earnings per share basis.

How many employees does RAPT Therapeutics have?

RAPT Therapeutics employs 81 workers across the globe.

What is RAPT Therapeutics' official website?

The official website for RAPT Therapeutics is www.rapt.com.

How can I contact RAPT Therapeutics?

RAPT Therapeutics' mailing address is 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 489-9000 or via email at inves[email protected].